Cite
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.
MLA
Tuckwell, Katie, et al. “Newly Diagnosed vs. Relapsing Giant Cell Arteritis: Baseline Data from the GiACTA Trial.” Seminars in Arthritis & Rheumatism, vol. 46, no. 5, Apr. 2017, pp. 657–64. EBSCOhost, https://doi.org/10.1016/j.semarthrit.2016.11.002.
APA
Tuckwell, K., Collinson, N., Dimonaco, S., Klearman, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., Salvarani, C., Unizony, S. H., & Stone, J. H. (2017). Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Seminars in Arthritis & Rheumatism, 46(5), 657–664. https://doi.org/10.1016/j.semarthrit.2016.11.002
Chicago
Tuckwell, Katie, Neil Collinson, Sophie Dimonaco, Micki Klearman, Daniel Blockmans, Elisabeth Brouwer, Maria C. Cid, et al. 2017. “Newly Diagnosed vs. Relapsing Giant Cell Arteritis: Baseline Data from the GiACTA Trial.” Seminars in Arthritis & Rheumatism 46 (5): 657–64. doi:10.1016/j.semarthrit.2016.11.002.